Лечение больных эрозивным эзофагитом современный взгляд на проблему

СтатьяМЕД СОВЕТ. 2018; № 6: 96–103. DOI:10.21518/2079-701X-2018-6-96-103

Морозов С.В.^[1]

Кучерявый Ю. А.^[2]

Кропочев В.С.^[1]

^[1]«Федеральный исследовательский центр питания и биотехнологии», Москва

^[2]Московский государственный медико-стоматологический университет им. А. И. Евдокимова

Гастроэзофагеальная рефлюксная болезнь – одно из наиболее широко встречающихся заболеваний гастроэнтерологического профиля. Выделяют несколько форм заболеваний, в том числе неэрозивную форму, эрозивный эзофагит, пищевод Барретта. В статье представлен обзор средств, использующихся для лечения эрозивной формы ГЭРБ и длительной поддерживающей терапии с позиций доказательной медицины. Основными целями лечения эрозивного эзофагита являются заживление повреждений слизистой оболочки пищевода, обеспечение длительной ремиссии заболевания, нормализация качества жизни больных. В настоящее время основой терапии эрозивного эзофагита являются ингибиторы протонной помпы (ИПП). Эти препараты используются на всех этапах лечения как для купирования симптомов, так и для заживления повреждений слизистой оболочки пищевода, а также в составе длительной поддерживающей терапии. Ввиду необходимости длительного использования ИПП закономерно возникают вопросы об их безопасности. В публикациях последних лет отмечена возможность увеличения рисков развития хронической болезни почек, инфаркта миокарда, пневмоний, развития дефицита кальция, магния, железа, витамина В12. В то же время анализ исследований, лежащих в основе наличия рисков длительного использования ИПП, выявляет ряд существенных недостатков, уменьшающих их доказательную ценность. В настоящей работе приведены данные о наиболее часто обсуждаемых рисках и их критическая оценка.

гастроэзофагеальная рефлюксная болезнь

лечение

эрозивный эзофагит

ингибиторы протонной помпы

декслансопразол

Безопасность

Болезнь

Боли

Больные

Витамины

Водородных ионов концентрация

Время

Декслансопразол

Деменция

Диагностика

Доказательная медицина

Железо

Животные

Издания

Изжога

Инфаркт миокарда

Кальций

Качество жизни

Магний

Миокард

Наблюдение

Неэрозивная рефлюксная болезнь

Новообразования

Обзор

Пищевода слизистая оболочка

Пневмония

Протонные насосы

Протоны

Работа

Раны и травмы

Риск

Хроническая болезнь

Эзомепразол

Эзофагит

Vakil N, van Zanten SV, Kahrilas P et al. The Montreal definition and classification of gas-troesophageal reflux disease: a global evidence-based consensus. American Journal of Gastroenterology, 2006, 101(8): 1900–1943.

Shaheen N J, Hansen R A, Morgan D Ret al. The burden of gastrointestinal and liver diseases, 2006. American Journal of Gastroenterology, 2006, 101(9): 2128–2138.

Dent J, El-Serag H B, Wallander M A, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 2005, 54(5): 710–717.

Blot WJ. Esophageal cancer trends and risk factors. Seminars in Oncology, 1994: 21(4): 403–410.

Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Alimentary Pharma-co logy and Therapeutics, 2006, 24(2): 259–272.

El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clinical Gastroenterology and Hepatology, 2007, 5(1): 17–26.

Engel L S, Chow WH, Vaughan TL et al. Population attributable risks of esophageal and gastric cancers. Journal of the National Cancer Institute, 2003, 95(18): 1404–1413.

Sontag SJ, Sonnenberg A, Schnell TG et al. The long-term natural history of gastroesophageal reflux disease. Journal of Clinical Gastroenterology, 2006, 40(5): 398–404.

Agrawal A, Castell D. GERD is chronic but not progressive. Journal of Clinical Gastroenterology, 2006, 40(5): 374–375.

Bardhan KD, Royston C, Nayyar AK. Reflux rising! An essay on witnessing a disease in evolution. Dig Liver Dis, 2006, 38: 163-168.

ass R, Ofman J. Gastroesophageal reflux disease–should we adopt a new conceptual framework? Am J Gastroenterol, 2002, 97: 1901-1909.

Nwokediuko SC. Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol, 2012, 2012: 391631. doi: 10.5402/2012/391631..
DOI: 10.5402/2012/391631

Морозов С.В., Кучерявый Ю.А. Гастроэзофагеальная рефлюксная болезнь: формы заболевания и особенности их лечения. Лечебное дело (журнал), 2015, 4: 21-30.

Исаков В.А., Морозов С.В., Ставраки Е.С., Комаров Р.С. Анализ Распространенности Изжоги: национальное эпидемиологическое исследование взрослого городского населения (АРИАДНА). Экспериментальная и клиническая гастроэнтерология, 2008, 1: 20-30.

Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther, 2000, 14: 669-690.

Ritschel WA. Antacids and Other Drugs in GI Diseases. Hamilton, IL, USA: Drug Intelligence Publications, Inc., 1984.

Washington N. Antacids and Anti-Reflux Agents. Boca Raton, FL, USA: CRC Press Inc., 1991: 127.

ones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. Lancet, 1989, 1: 47-51.

Vatier J, Celice-Pingaud C, Farinotti R. A com-puterized artificial stomach model to assess sodium alginate-induced pH gradient. Int J Pharmaceut, 1998, 163: 225-9.

night LC, Maurer AH, Ammar IA et al. Use of 111In-labeled alginate to study the pH dependence of alginic acid anti-esophageal refux barrier. Int J Rad Appl Instrum (B), 1988, 15: 563-71.

May HA, Wilson CG, Hardy JG. Monitoring radiolabeled antacid preparations in the stomach. Inter J Pharmaceutics, 1984, 19: 169-76.

Malmud LS, Charles ND, Littlefield J, et al. The mode of action of alginic acid compound in the reduction of gastroesophageal reflux. J Nuc Med, 1979, 20: 1023-8.

Goodall JS, Orwin JM, Imrie MJ. A combined pH and X-ray study of liquid alginate/antacid formulation using a novel X-ray contrast medium. Acta Therapeutica, 1977, 3: 141-53.

Washington N, Parker MA, Steele RJC, et al. Time to onset of action of sodium alginate, ranitidine, omeprazole and water based on oesophageal pH. Gastroenterology, 1999, 116: A350(Abstract).

Uzan M, Uzan S, Surean C, Richard-Berthe C. Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension. Rev Fr Gynecol Obst, 1988, 83: 569-72.

Lang GD, Dougall A. Comparative study of Algicon suspension and magnesium trisilicate mixture in the treatment of reflux dyspepsia of pregnancy. Br J Clin Pract, 1990, 66: 48-51.

Modlin IM, Hunt RH, Malfertheiner P et al. Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group. Digestion, 2009, 80: 74–88.

Langen ML, van Zanten SV. Does the evidence show that prokinetic agents are effective in healing esophagitis and improving symptoms of GERD? Open Medicine, 2007, 1(3): 181–3.

Kim YS, Kim TH, Choi CS et al. Effect of ito-pride, a new prokinetic, in patients with mild GERD: A pilot study. World J Gastroenterol, 2005, 11(27): 4210-4214.

Ndraha S. Combination of PPI with a prokinetic drug in GERD. Acta Med Indones-Indones J Intern Med, 2011, 43 (4): 233-236.

Manzotti ME, Catalano HN, Serrano FA et al. Prokinetic drug utility in the treatment of gas-troesophageal reflux esophagitis: a systematic review of randomized controlled trials. Open Med, 2007, 1(3): 171-80.

Jones DB, Howden CW, Burget DW, et al. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut, 1987, 28: 1120–1127.

Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev, 2007, 2: CD003244.

Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М.: ИКЦ «Академкнига», 2001. 304 с.

Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology, 2008, 135: 1383–1391.

Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol, 2013, 108: 308–328.

Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut, 1992 Jan, 33(1): 118-24.

Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2000, 14: 861–7.

Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci, 2002, 47: 954–8

Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, et al. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion, 2003, 68: 184–8.

Miner PJr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol, 2003, 98: 2616–20.

Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol, 2004, 60: 531–9.

Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study. Aliment Pharmacol Ther, 2005, 21: 963–7

Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2005, 22: 129–34

Simon B, Muller P, Pascu O, et al. Intra-oeso phageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol, 2003, 15: 791–9.

Морозов С.В., Исаков В.А., Цодикова О.М. Влияние эзомепразола и рабепразола на закисление пищевода у больных гастроэзофагеальной рефлюксной болезнью, интенсивно метаболизирующих ингибиторы протонного насоса. Терапевтический архив, 2005, 2: 21-25

Kalaitzakis E, Björnsson E. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Therapeutics and Clinical Risk Management, 2007, 3(4): 653-663.

Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther, 2003, 18(6): 559-68.

Li MJ, Li Q, Sun M, Liu LQ. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine (Baltimore), 2017, 96(39): e8120. doi: 10.1097/MD.0000000000008120. PubMed PMID: 28953640..
DOI: 10.1097/MD.0000000000008120. PubMed

Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the singledose pharmacodynamics of dual delayedrelease dexlansoprazole 60mg and delayedrelease esomeprazole 40 mg. Clin Exp Gastroenterol, 2011, 4: 213–20.

DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol, 2005, 100: 190–200

Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet, 2006, 367: 2086–100.

Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol, 2001, 96: 27–34.

Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther, 2003, 17: 333–41.

Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther, 2005, 22: 803–11.

Devault KR, Johanson JF, Johnson DA, et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol, 2006, 4: 852–9.

Park JH, H Park, Lee DH et al. A randomized, double blinded, clinical trial to assess the efficacy and cost effectiveness of omeprazole compared to rabeprazole in the maintenance therapy of patients with gastroesophageal reflux disease. J Neurogastroenterol Motil, 2013, 19(2): 219–226.

Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet, 1995, 29: 192- 209.

Sjöstedt S, Befrits R, Sylvan A, et al Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther, 2005, 22(3): 183-91.

Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology, 2017, 152(4): 706- 715.

Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med, 2016, 176: 238–246.

Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol, 2016, 27: 3153-316.

Badiola N, Alcalde V, Pujol A, et al. The protonpump inhibitor lansoprazole enhances amyloid beta production. PLoS One, 2013, 8: e58837.

Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci, 2015, 265: 419–428.

Gomm W, von Holt K, Thome F, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol, 2016, 73: 410–416.

Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA, 2006, 296: 2947–2953.

Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol, 2012, 107: 1361–1369.

Maggio M, Lauretani F, Ceda GP, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone, 2013, 57: 437–442.

Targownik L, Luo Y, Goertzen A, et al. Comparing Bone Structure and Bone Metabolism Between Long-Term Proton Pump Inhibitor Users and Non-Users. Gastroenterology, 2015, 148: S-153.

Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med, 2010, 363: 1909–1917.

Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation, 2013, 128: 845–853.

Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One, 2015, 10: e0124653.

Rosen R, Hu L, Amirault J, et al. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oro-pharyngeal microflora. J Pediatr, 2015, 166: 917–923.

Lambert AA, Lam JO, Paik JJ, et al. Risk of community acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One, 2015, 10: e0128004.

Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a rand-omized, controlled trial (OBERON). Heart, 2011, 97: 797–802.

Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther, 2015, 42: 607–613.

O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. American Journal of Medicine, 2005, 118: 778–781.

Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med, 1967, 66: 917–923.

Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. Journal of the American College of Nutrition, 1995, 14: 364–368.

Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Alimentary Pharmacology & Therapeutics, 1998, 12: 83–98.

Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med, 2006, 355: 1834–1836.

Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 2013, 310: 2435–2442.

Язык текста: Русский

ISSN: 2079-701X